Non-alcoholic Steatohepatitis Treatment Market Size Worth $ 90.97 Billion by 2034 | CAGR: 28.0%
The non-alcoholic steatohepatitis treatment market size is expected to reach USD 90.97 billion by 2034, according to a new study by Polaris Market Research. The report “Non-alcoholic Steatohepatitis Treatment Market Share, Size, Trends, Industry Analysis Report: By Drug, Disease Stage, Distribution Channel (Hospital Pharmacies, Retail and Specialty Pharmacies, and Other Pharmacies), and Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa); Market Forecast, 2025–2034” gives a detailed insight into current market dynamics and provides analysis on future market growth.
The non-alcoholic steatohepatitis (NASH) treatment market growth is attributed to the rising prevalence of risk factors such as obesity, type 2 diabetes, and metabolic syndrome, strongly linked to the development of NASH. The rising prevalence of NASH across the world is expected to create ample market opportunities for pharmaceutical companies.
The NASH treatment market is expected to experience a robust growth trajectory, increasing research efforts and innovative therapies targeting the complex pathophysiology of NASH, including liver inflammation, fibrosis, and insulin resistance. The market size for NASH treatments is expanding, with the global incidence of NASH continuing to rise, particularly in regions such as North America, Europe, and Asia Pacific.
Do you have any questions? Would you like to request a sample or make an inquiry before purchasing this report? Simply click the link below: Download Sample Report
The non-alcoholic steatohepatitis treatment market outlook is optimistic, with a growing number of drugs, including Obeticholic Acid (OCA), Semaglutide, Lanifibranor, and Vitamin E, advancing through clinical trials and receiving regulatory approvals. The expansion of healthcare access, increased awareness about NASH, and the growing focus on liver diseases contribute to the rising demand for NASH treatments. Moreover, the aging population, especially in developed countries, accelerates the need for innovative therapies. Advancements in diagnostics and treatment options are set to drive significant expansion, offering considerable growth potential and opportunities for stakeholders within the healthcare industry.
Non-alcoholic Steatohepatitis Treatment Market Report Highlights
- In terms of drug, in 2024, the vitamin E and pioglitazone segment accounted for the largest share of the non-alcoholic steatohepatitis (NASH) treatment market revenue due to its well-established efficacy in reducing liver inflammation and improving insulin sensitivity in NASH patients.
- The retail and specialty pharmacies systems segment, based on distribution channel, is expected to witness the highest CAGR during the forecast period due to its accessibility and ability to provide specialized medications and patient support for NASH treatment.
- In 2024, North America dominated the non-alcoholic steatohepatitis treatment market share due to the high prevalence of obesity and type 2 diabetes, coupled with strong healthcare infrastructure and substantial investment in liver disease research.
- The Asia Pacific market is expected to witness significant growth during the forecast period due to increasing healthcare expenditure and greater awareness of liver disease management.
- A few global key market players are Intercept Pharmaceuticals, Inc.; Galmed Pharmaceuticals Ltd; Inventiva; AbbVie Inc.; Galectin Therapeutics Inc.; Madrigal Pharmaceuticals Inc (Madrigal); NGM Biopharmaceuticals, Inc.; Novo Nordisk A/S; The Bristol-Myers Squibb Company; and Gilead Sciences, Inc.
Polaris Market Research has segmented the non-alcoholic steatohepatitis treatment market report on the basis of drug, disease stage, distribution channel, and region:
By Drug Outlook (Revenue, USD Billion; 2020–2034)
- Vitamin E and Pioglitazone
- Obeticholic Acid (OCA)
- Lanifibranor
- Semaglutide
- Resmetirom
- Aramchol
- Cenicriviroc
- Other Drugs
By Disease Stage Outlook (Revenue, USD Billion; 2020–2034)
- NASH Stage F0
- NASH Stage F1
- NASH Stage F2
- NASH Stage F3
- NASH Stage F4
By Distribution Channel Outlook (Revenue, USD Billion; 2020–2034)
- Hospital Pharmacies
- Retail and Specialty Pharmacies
- Other Pharmacies
By Regional Outlook (Revenue, USD Billion; 2020–2034)
- North America
- US
- Canada
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Russia
- Netherlands
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- South Korea
- Indonesia
- Malaysia
- Australia
- Rest of Asia Pacific
- Latin America
- Argentina
- Brazil
- Mexico
- Rest of Latin America
- Middle East & Africa
- UAE
- Saudi Arabia
- Israel
- South Africa
- Rest of Middle East & Africa
Non-alcoholic Steatohepatitis Treatment Market Report Scope
|
Report Attributes |
Details |
|
Market Size Value in 2024 |
USD 7.70 billion |
|
Market Size Value in 2025 |
USD 9.85 billion |
|
Revenue Forecast by 2034 |
USD 90.97 billion |
|
CAGR |
28.0% from 2024 to 2032 |
|
Base Year |
2024 |
|
Historical Data |
2020–2023 |
|
Forecast Period |
2025–2034 |
|
Quantitative Units |
Revenue in USD billion and CAGR from 2025 to 2034 |
|
Report Coverage |
Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends |
|
Segments Covered |
|
|
Regional Scope |
|
|
Competitive Landscape |
|
|
Report Format |
|
|
Customization |
Report customization as per your requirements with respect to countries, regions, and segmentation. |
|
For Specific Research Requirements |
